Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AOZORA study: Ozoralizumab effects on bone structure in rheumatoid arthritis
jRCTs071230067Active, not recruiting
- Sponsor
- Taisho Pharmaceutical
- Start
- Oct 2023
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of ozoralizumab in rheumatoid arthritis (RA), sponsored by Taisho Pharmaceutical. Primary endpoint: Volumetric change in bone erosions by HR-pQCT at 52 weeks. Started Oct 2023; status: active, not recruiting.
02
Drugs
ozoralizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCTs071230067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071230067.